For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates//, according to a new study. The study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes – a significant risk associated with tamoxifen.
Hormone modulating therapies have made a significant impact on the survival rates of women with estrogen-sensitive breast cancer over the last two decades. The drugs are used as adjuvant to primary surgical treatment for a period of five years.
Tamoxifen was the first estrogen modulator shown to increase survival and reduce the risk of breast cancer recurrence. However, tamoxifen is associated with increased risk of death from other causes, such as strokes and endometrial cancer. Despite this risk, tamoxifen and another drug in this class, raloxifene, remain an extensively used and popular treatment.
Aromatase inhibitors, such as aminoglutethimide and anastrozole, work in a different way to lower estrogen levels. Recent evidence shows aromatase inhibitors used alone or in follow-up after two years of tamoxifen therapy demonstrates clear and, in some cases, improved reduction of recurrence risk. However, there is conflicting evidence about mortality benefits.
Led by Professor Francesco Boccardo, M.D. of the National Cancer Research Institute and the University of Genoa in Italy, researchers pooled data from two studies (828 women) comparing five year treatment with tamoxifen alone (415 women) or tamoxifen for two to three years followed by an aromatase inhibitor for the remaining treatment period (413 women).
Dr. Boccardo and his colleagues found that compared to treatment with tamoxifen alone, all cause mortality risk and breast cancer-related mortality risk both fell significantly for women switching to an aromatase inhibitor. In addition, there was no increased risk of dePage: 1 2 Related medicine news :1
. Early detection of prostate cancer2
. Early detection of heart attack3
. Early puberty linked to nutrition4
. Early Clue to Down Syndrome 5
. Early delivery can prevent cancer6
. Early puberty more resistance
. Early menopause- The cause8
. Early menopause- The cause9
. Early Warning System For Breast Cancer10
. Early therapy aids eyesight11
. Early detection of colorectal cancer may be hindered by coloured toilet disinfectants